XORTX Therapeutics Inc. (XRTX)

Market Cap	2.56M +261.1%
Revenue (ttm)	n/a
Net Income	-2.66M
EPS	-0.56
Shares Out	6.96M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	123,241
Open	0.38625
Previous Close	0.3450
Day's Range	0.3456 - 0.4000
52-Week Range	0.3450 - 1.4100
Beta	0.10
Analysts	n/a
Price Target	n/a
Earnings Date	May 15, 2026

About XRTX

XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for th...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 3
• Stock Exchange: NASDAQ
• Ticker Symbol: XRTX
• Website: https://www.xortx.com